Novartis AG (VTX:NOVN) received a CHF 90 price target from research analysts at Baader Bank in a note issued to investors on Friday. The firm presently has a “buy” rating on the stock.

Several other equities research analysts have also recently weighed in on the company. Jefferies Group LLC set a CHF 103 price target on Novartis AG and gave the company a “buy” rating in a research report on Friday, June 23rd. Barclays PLC set a CHF 65 price target on Novartis AG and gave the company a “sell” rating in a research report on Friday, June 2nd. Deutsche Bank AG set a CHF 78 price target on Novartis AG and gave the company a “neutral” rating in a research report on Wednesday, June 21st. Morgan Stanley set a CHF 75 price target on Novartis AG and gave the company a “sell” rating in a research report on Monday, May 29th. Finally, Credit Suisse Group set a CHF 77 price target on Novartis AG and gave the company a “sell” rating in a research report on Wednesday, July 5th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and seven have assigned a buy rating to the stock. Novartis AG currently has an average rating of “Hold” and a consensus target price of CHF 84.60.

Novartis AG (NOVN) traded up 0.30% during trading on Friday, reaching CHK 82.60. 3,161,906 shares of the company’s stock traded hands. Novartis AG has a 52-week low of CHK 67.40 and a 52-week high of CHK 84.35. The company’s 50 day moving average is CHK 80.43 and its 200-day moving average is CHK 76.91.

COPYRIGHT VIOLATION NOTICE: “Baader Bank Reiterates CHF 90 Price Target for Novartis AG (VTX:NOVN)” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this article on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/08/06/baader-bank-reiterates-chf-90-price-target-for-novartis-ag-vtxnovn.html.

About Novartis AG

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Analyst Recommendations for Novartis AG (VTX:NOVN)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.